Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL.

Journal of lipid research·2020
Same author

Weight Loss and Exercise Alter the High-Density Lipoprotein Lipidome and Improve High-Density Lipoprotein Functionality in Metabolic Syndrome.

Arteriosclerosis, thrombosis, and vascular biology·2017
Same author

Corrigendum to "Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/GPx1-deficient mice" [Atherosclerosis 243/2 (2015) 598-608].

Atherosclerosis·2016
Same author

Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma.

Data in brief·2016
Same author

Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia.

Journal of lipid research·2016
Same author

Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies.

Clinical and translational allergy·2016

Related Experiment Video

Updated: May 24, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Exercise-induced bronchoconstriction update: therapeutic management.

Sheldon Spector1, Ricardo Tan

  • 1University of California, Los Angeles, Medical Center, Los Angeles, California 90025, USA.

Allergy and Asthma Proceedings
|February 29, 2012
PubMed
Summary

Effective management of exercise-induced bronchoconstriction (EIB) involves prevention and treatment, utilizing nonpharmacologic and pharmacologic strategies. Pre-exercise warm-ups and certain dietary interventions show promise for EIB control.

More Related Videos

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

Related Experiment Videos

Last Updated: May 24, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

Area of Science:

  • Sports Medicine
  • Pulmonology
  • Pharmacology

Background:

  • Exercise-induced bronchoconstriction (EIB) requires comprehensive management strategies.
  • Underlying asthma and bronchial hyperresponsiveness are key factors in EIB.
  • Both nonpharmacologic and pharmacologic approaches are essential for EIB management.

Purpose of the Study:

  • To outline current best practices for managing exercise-induced bronchoconstriction.
  • To review preventive and treatment modalities for EIB.
  • To discuss the role of various pharmacologic agents and interventions in EIB.

Main Methods:

  • Review of nonpharmacologic strategies, including pre-exercise warm-up and dietary interventions (fish oil, vitamin D, ascorbic acid).
  • Evaluation of pharmacologic treatments, focusing on beta 2-agonists, leukotriene inhibitors, and mast cell stabilizers.
  • Discussion of medication tolerance and potential interactions, including inhaled corticosteroids.

Main Results:

  • Pre-exercise warm-up leverages the refractory period for EIB prevention.
  • Dietary interventions like fish oil, vitamin D, and ascorbic acid show promising results.
  • Beta 2-agonists are highly effective but require intermittent use to prevent tolerance; leukotriene inhibitors and mast cell stabilizers are less effective.
  • Tolerance to beta 2-agonists is not mitigated by inhaled corticosteroids.

Conclusions:

  • A multifaceted approach combining nonpharmacologic and pharmacologic methods is crucial for managing EIB.
  • Intermittent use of beta 2-agonists is recommended to maintain effectiveness.
  • Further research is needed to understand EIB pathogenesis in elite athletes without asthma and the impact of leukotriene inhibitors on tolerance.